Andriy Obrizan became the CEO of the PrJSC Pharmaceutical firm Darnitsa, the company’s press service has reported.
Obrizan headed the project of an international company with the headquarters in Zurich (Switzerland) that develops innovative solutions for healthcare, communication and security industries.
Darnitsa’s new top manager also used to work in leading Ukrainian and international pharmaceutical companies Arterium Corporation, Biofarma, TEVA/PGT Healthcare, Richter Gedeon. He also has a nine-year experience of work in practical medicine.
Andriy Obrizan sees strengthening Darnitsa’s leading position on the domestic market, establishing the partnership with the leading international producers and supplementing the product portfolio with the modern, effective and in the same time affordable pharmaceuticals, as the main goals on his new position.
"A true professional has joined our team. He has a comprehensive experience not only in pharm industry but also medicine, management, finances, marketing, innovative products development," said Dmytro Shymkiv, the head of the executive board at PrJSC Pharmaceutical firm Darnitsa managing company.
Shymkiv joined the executive board of Darnitsa in September 2018. Before that he used to work as the deputy head of the Presidential Administration of Ukraine, and earlier he had headed the Ukrainian branch of Microsoft Corporation.
Svitlana Didenko, the former CEO of the PrJSC Pharmaceutical firm Darnitsa, will become a member of Darnitsa's supervisory council and concentrate on the strategic development issues.
The PrJSC Pharmaceutical firm Darnitsa was founded in 1930. It is a leader of Ukraine’s pharmaceutical market by volume of pharmaceutical output. The company’s portfolio includes more than 250 names of pharmaceutical products. In 2017, the company posted 2.53bn hryvnyas in sales, which is 19% more than in 2016.
The company’s net profit in 2017 was 342.111m hryvnyas. The Zagoriys family, including Hlib Zagoriy, a member of the Ukrainian parliament of the eighth convocation, is the ultimate beneficiary of the PrJSC Pharmaceutical firm Darnitsa.